Literature DB >> 2834843

In vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis.

J M Dickinson1, D A Mitchison.   

Abstract

The bactericidal activity of six new rifamycin derivatives--rifabutin (RBU), FCE 22250 (F22), rifapentine (RPE), CGP 29861 (C29), CGP 7040 (C70) and CGP 27557 (C27) and rifampicin (RMP)--have been measured against log phase and, as a better test of sterilising activity, against stationary phase cultures of Mycobacterium tuberculosis, H37Rv. The order of activity of 1.0 and 0.2 mg/l rifamycin against log phase cultures was RMP greater than RPE & C27 greater than RBU & C29 greater than C70. The order of activity of 1.0 and 0.4 mg/l, adjusted for stability of the rifamycin, against stationary phase cultures was F22 & RMP greater than RBU greater than RPE greater than C27 & C29 greater than C70. Viable counts were done during and after pulsed exposures of 6, 24 or 96 h to C29 and RMP. The curves were similar though C29 was less bactericidal and the lag period before recovery was 1-2 days longer. F22, having high bactericidal activity against stationary organisms and a long half-life, was considered likely to be the most effective sterilising drug.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2834843     DOI: 10.1016/0041-3879(87)90054-7

Source DB:  PubMed          Journal:  Tubercle        ISSN: 0041-3879


  9 in total

Review 1.  Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections.

Authors:  E Nuermberger; J Grosset
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-13       Impact factor: 3.267

2.  Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis.

Authors:  B P Kelly; S K Furney; M T Jessen; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

3.  Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages.

Authors:  N Mor; B Simon; L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

4.  Differential In Vitro Activities of Individual Drugs and Bedaquiline-Rifabutin Combinations against Actively Multiplying and Nutrient-Starved Mycobacterium abscessus.

Authors:  Jin Lee; Nicole Ammerman; Anusha Agarwal; Maram Naji; Si-Yang Li; Eric Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

5.  Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages.

Authors:  N Mor; B Simon; N Mezo; L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

6.  Evaluation of once-weekly therapy for tuberculosis using isoniazid plus rifamycins in the mouse aerosol infection model.

Authors:  J V Brooks; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

7.  Construction of a bioluminescent mycobacterium and its use for assay of antimycobacterial agents.

Authors:  P W Andrew; I S Roberts
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

8.  Effectiveness of rifabutin alone or in combination with isoniazid in preventive therapy of mouse tuberculosis.

Authors:  D Jabès; C Della Bruna; R Rossi; P Olliaro
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

9.  Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis.

Authors:  Ramesh Jayaram; Sheshagiri Gaonkar; Parvinder Kaur; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharat; R K Shandil; E Kantharaj; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.